Apellis Pharmaceuticals (NASDAQ:APLS) initiates a Phase 1/2 clinical trial
evaluating C3 inhibitor APL-9 in hospitalized COVID-19 patients with
respiratory failure, including acute respiratory distress syndrome
(ARDS).
The primary objective of the 66-subject study is
the safety of APL-9 added to standard-of-care treatment. Secondary
measures include length of hospital stay, overall survival and time on
oxygen therapy or mechanical ventilation.
https://seekingalpha.com/news/3578194-apellis-launches-study-of-aplminus-9-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.